William Blair Reiterates Market Perform Rating for Moderna (NASDAQ:MRNA)

Moderna (NASDAQ:MRNA - Get Free Report)'s stock had its "market perform" rating reaffirmed by William Blair in a research report issued on Monday,RTT News reports.

MRNA has been the subject of several other research reports. Bank of America reduced their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. JPMorgan Chase & Co. dropped their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a report on Thursday, May 22nd. Barclays cut their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. Morgan Stanley decreased their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. Finally, UBS Group reduced their target price on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $53.58.

Moderna Price Performance

Shares of NASDAQ MRNA traded up $1.34 during mid-day trading on Monday, reaching $27.46. 8,472,537 shares of the company traded hands, compared to its average volume of 8,263,579. Moderna has a fifty-two week low of $23.15 and a fifty-two week high of $158.82. The firm has a market cap of $10.62 billion, a PE ratio of -2.96 and a beta of 1.86. The stock has a fifty day simple moving average of $26.11 and a 200-day simple moving average of $33.57.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The firm had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. During the same period last year, the company posted ($3.07) EPS. The firm's quarterly revenue was down 35.3% on a year-over-year basis. As a group, analysts predict that Moderna will post -9.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MRNA. FMR LLC boosted its stake in Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after purchasing an additional 1,282,469 shares during the period. Theleme Partners LLP lifted its position in shares of Moderna by 1.0% during the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock worth $303,819,000 after buying an additional 72,028 shares during the period. Geode Capital Management LLC raised its stake in Moderna by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after acquiring an additional 171,774 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Moderna by 17.5% during the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock valued at $166,801,000 after acquiring an additional 877,162 shares during the period. Finally, Norges Bank bought a new stake in shares of Moderna in the 4th quarter worth about $163,833,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.